Diluted HEPS from continuing operations increased to 139.0cps (+60.3% y-y). Normalised EPS from continuing operations increased to 132.3cps (+48.5% y-y).
Turnover from continuing operations +12.7% y-y to R25.5bn.
Total expense growth of 12.0% y-y to R22.9bn, with expenses-to-sales down to 89.9% in FY24 (FY23: 90.4%).
OPM increased from 10.8% to 11.4%.
Dividend of 720cps (Dividend for the year of 50cps, special dividend of 70cps, and special dividend on the sale of Alliance Medical of 600cps).
Gross debt decreased to R4.4bn in FY24, with net cash increasing to R2.5bn.
Concluded a transaction to sub-license one of LMI’s early-stage novel products (RM2) for USD36 million (R665 million).
Acute hospitals PPDs grew 1.6% y-y, benefitting from new network deals which commenced in January 2023. This translated into higher occupancies across acute hospital facilities.
Strong growth in Neuraceq doses sold of 91.9% y-y.
